Edition:
India

Shanghai Fosun Pharmaceutical Group Co Ltd (2196.HK)

2196.HK on Hong Kong Stock

23.90HKD
26 Jun 2019
Change (% chg)

HK$1.20 (+5.29%)
Prev Close
HK$22.70
Open
HK$22.85
Day's High
HK$24.10
Day's Low
HK$22.45
Volume
2,853,505
Avg. Vol
3,564,710
52-wk High
HK$45.65
52-wk Low
HK$19.76

Latest Key Developments (Source: Significant Developments)

Shanghai Fosun Pharmaceutical's Unit Plans To Invest For Almost 98% Stake In Chengdu Medical Firm
Tuesday, 25 Jun 2019 

June 25 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>2196.HK::SAYS ITS UNIT PLANS TO INVEST UP TO 746.7 MILLION YUAN ($108.55 million) IN ALMOST 98% STAKE IN CHENGDU MEDICAL FIRM.  Full Article

Shanghai Fosun Pharmaceutical's Q1 Net Profit Up 0.9 Percent Y/Y
Monday, 29 Apr 2019 

April 29 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>2196.HK::SAYS Q1 NET PROFIT UP 0.9 PERCENT Y/Y.  Full Article

BRIEF-Shanghai Fosun Pharmaceutical's Units Plan Project, Sign Licence Agreement With UK Firm
Tuesday, 9 Apr 2019 

Adds bullet point, link:SAYS UNIT PLANS BIO-PHARMA PROJECT WITH INVESTMENT OF UP TO 1.0 BILLION YUAN ($149.09 million).SAYS BOARD APPROVES UNIT TO SIGN LICENSE AGREEMENT WITH RENEURON LIMITED IN U.K..  Full Article

Reneuron Group Partners With Fosun Pharma In China
Tuesday, 9 Apr 2019 

April 9 (Reuters) - ReNeuron Group PLC ::RENEURON PARTNERS WITH FOSUN PHARMA IN CHINA.RENEURON TO RECEIVE UPFRONT, NEAR TERM AND ESTIMATED SUCCESS-BASED MILESTONE PAYMENTS OF £80.0 MILLION.FOSUN PHARMA WILL FULLY FUND DEVELOPMENT OF RENEURON'S CTX AND HRPC CELL THERAPY PROGRAMMES IN CHINA.RENEURON WILL ALSO RECEIVE TIERED ROYALTIES AT RATES BETWEEN 12% AND 14% ON SALES OF LICENSED PRODUCTS IN CHINESE MARKET.  Full Article

Shanghai Fosun Pharmaceutical Approved Proposed Issuance Of Corporate Bonds
Friday, 29 Mar 2019 

March 29 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::BOARD CONSIDERED AND APPROVED PROPOSED ISSUANCE OF CORPORATE BONDS.PROPOSED THAT SIZE OF PROPOSED ISSUANCE WILL NOT BE MORE THAN RMB10.0 BILLION.  Full Article

Shanghai Fosun Pharmaceutical Group Says Board Proposed Re-Election Of Executive Directors
Monday, 25 Mar 2019 

March 25 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::PROPOSED RE-ELECTION OF CHEN QIYU, YAO FANG AND WU YIFANG, AS EXECUTIVE DIRECTORS OF EIGHTH SESSION OF BOARD.BOARD PROPOSED TO APPOINT XU XIAOLIANG AND LIANG JIANFENG AS NON-EXECUTIVE DIRECTORS OF EIGHTH SESSION OF BOARD.WANG QUNBIN WILL RETIRE FROM HIS CURRENT POSITION AS A NON-EXECUTIVE DIRECTOR.ZHANG XUEQING WILL RETIRE FROM HIS CURRENT POSITION AS A NON-EXECUTIVE DIRECTOR.  Full Article

BRIEF-Shanghai Fosun Pharmaceutical's 2018 Net Profit Down 13.3 Percent Y/Y
Monday, 25 Mar 2019 

Refiles with additional bullet point, link:SAYS 2018 NET PROFIT DOWN 13.3 PERCENT Y/Y.SAYS IT AND AFFILIATE AGREE TO BOOST BIOTECH FIRM'S CAPITAL BY A COMBINED 500 MILLION YUAN TO 790 MLN YUAN.  Full Article

Shanghai Fosun Pharmaceutical Says Fosun High Tech Acquired Additional H Shares
Wednesday, 4 Jul 2018 

July 4 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::FOSUN HIGH TECH ACQUIRED ADDITIONAL 500,000 H SHARES AT AVERAGE PURCHASE PRICE OF HK$39.92 PER H SHARE.DEAL FOR ABOUT RMB16.95 MILLION.  Full Article

Dova Pharmaceuticals Signs Distribution Agreement With Fosun Pharma For Mainland China And Hong Kong
Monday, 19 Mar 2018 

March 19 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS SIGNS EXCLUSIVE DISTRIBUTION AGREEMENT WITH FOSUN PHARMA FOR MAINLAND CHINA AND HONG KONG.DOVA PHARMACEUTICALS - ‍DEAL THROUGH UNIT GRANTING FOSUN PHARMA EXCLUSIVE DEVELOPMENT,DISTRIBUTION RIGHTS OF AVATROMBOPAG IN MAINLAND CHINA, HONG KONG​.DOVA PHARMACEUTICALS INC - ‍TERMS OF TRANSACTION INCLUDE AN UPFRONT PAYMENT, MILESTONE PAYMENTS, AND A FIXED TRANSFER PRICE FOR PRODUCT SUPPLIED​.  Full Article

Shanghai Fosun Pharmaceutical Group unit gets sole license on research of anticarcinogen in China
Wednesday, 14 Feb 2018 

Feb 14 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS> ::Says its unit signs License and Option Agreement with U.S. company Galaxy Biotech, LLC, to get sole license on research and development of monoclonal antibody for anticarcinogen new drug in China .  Full Article